Changes in root morphology indexes and root dry weight of different treatments in September 2023 (Second planting). by Hongyi Pan (5706971)

Subjects:

Relationship between soil three phases and ideal points in different treatments before and after the experiment. by Hongyi Pan (5706971)

Subjects:

Changes in average BD, PD, and TP of rhizosphere soil (0–60 cm) under different treatments before and after the experiment. by Hongyi Pan (5706971)

Subjects:

Developing an Arene Binuclear Ruthenium(II) Complex to Induce Ferroptosis and Activate the cGAS-STING Pathway: Targeted Inhibiting Growth and Metastasis of Triple Negative Breast C... by Gang Xu (219455)

Subjects:

Pre-RT and post RT D-dimer levels in associated with prognostic significance. by Huriye Senay Kiziltan (22298378)

Subjects:

Increased or reduced ATGL-1 activity does not significantly change <i>N. parisii</i> growth. by Hala Tamim El Jarkass (16625309)

Subjects:

Significant Wilcoxon test results of the Task 1 Nasa TLX data, differences between feedback ON and OFF. by Mucahit Gemici (21519313)

Average pain level among Jordanian women with breast cancer N = 150. by Nijmeh AL-Atiyyat (19859709)

Subjects:

Table 1_Ferroptosis-related gene signature-based subtype identification of triple-negative breast cancer to prioritize treatment strategies.xlsx by Yongzhen Chen (2901503)

“…However, little is known about the role of ferroptosis in chemotherapy and immune checkpoint inhibitor (ICI) therapy responses, as well as the molecular subtype identification of triple-negative breast cancer (TNBC).</p>Methods<p>We performed unsupervised clustering to stratify patients with TNBC in the Fudan University Shanghai Cancer Center (FUSCC) TNBC cohort into distinct ferroptosis-related subtypes according to the expression of eight ferroptosis-related genes (FRGs): EMC2, FTH1, HMOX1, LPCAT3, NOX4, SOCS1, BAP1, and ISCU. …”

a. Positive ion mode volcanic map (color and up-regulation correlation with differential metabolites) (A) Mild PTOA Group VS Severe PTOA Group (B) Mild PTOA Group VS Normal Group (... by Peng-fei Han (694841)

Subjects:

Data Sheet 1_Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation.docx by Anisha Jain (14306740)

“…Introduction<p>Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer to treat because it lacks the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). …”

Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked. by Indrani Bera (804948)

“…<p>Average % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for brown non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”

Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked. by Indrani Bera (804948)

“…<p>Average of % peptides counts for different classes of proteins at different germination time points and significant p-value indicated as compared to soaked sample (*p< 0.05, **p<0.01, ***p<0.001) for garbanzo non-trypsinised with shades of green showing increase and red showing decrease with respect to soaked.…”

Figure 5 from Zinc-alpha-2-glycoprotein Secreted by Triple-Negative Breast Cancer Promotes Peritumoral Fibrosis by Surbhi Verma (454998)

Image 2_Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.jpeg by Yeon Hee Park (10259882)

“…</p>Results<p>A consensus was reached for 80% of the statements (20/25) and aligned with the international guidelines. A significant gap was observed between real-world practices and the recommendations of the steering committee members in discussing contralateral risk reducing mastectomy with the patients as a part of standard practice, considering poly ADP-ribose polymerase inhibitor (PARPi) + immunotherapy for early triple negative breast cancer (eTNBC) patients with BRCA variants who don’t achieve pathological complete response after neoadjuvant chemotherapy + immunotherapy, use of adjuvant PARPi in patients with BRCA germline pathogenic variants in eTNBC who have achieved pathological complete response from neoadjuvant therapy, and preference for endocrine therapy + PARPi over endocrine therapy + cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as escalated adjuvant treatment for BRCA pathogenic variants with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-negative) early breast cancer.…”

Image 1_Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.jpeg by Yeon Hee Park (10259882)

“…</p>Results<p>A consensus was reached for 80% of the statements (20/25) and aligned with the international guidelines. A significant gap was observed between real-world practices and the recommendations of the steering committee members in discussing contralateral risk reducing mastectomy with the patients as a part of standard practice, considering poly ADP-ribose polymerase inhibitor (PARPi) + immunotherapy for early triple negative breast cancer (eTNBC) patients with BRCA variants who don’t achieve pathological complete response after neoadjuvant chemotherapy + immunotherapy, use of adjuvant PARPi in patients with BRCA germline pathogenic variants in eTNBC who have achieved pathological complete response from neoadjuvant therapy, and preference for endocrine therapy + PARPi over endocrine therapy + cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as escalated adjuvant treatment for BRCA pathogenic variants with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-negative) early breast cancer.…”

Data Sheet 1_Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management.doc by Yeon Hee Park (10259882)

“…</p>Results<p>A consensus was reached for 80% of the statements (20/25) and aligned with the international guidelines. A significant gap was observed between real-world practices and the recommendations of the steering committee members in discussing contralateral risk reducing mastectomy with the patients as a part of standard practice, considering poly ADP-ribose polymerase inhibitor (PARPi) + immunotherapy for early triple negative breast cancer (eTNBC) patients with BRCA variants who don’t achieve pathological complete response after neoadjuvant chemotherapy + immunotherapy, use of adjuvant PARPi in patients with BRCA germline pathogenic variants in eTNBC who have achieved pathological complete response from neoadjuvant therapy, and preference for endocrine therapy + PARPi over endocrine therapy + cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as escalated adjuvant treatment for BRCA pathogenic variants with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-negative) early breast cancer.…”

Table 1_Elevated KNSTRN as a potential indicator for triple-negative breast cancer progression and immune infiltration.docx by Yurong Song (491937)

“…</p>Results<p>KNSTRN was significantly overexpressed in TNBC compared to those in other breast cancer subtypes and normal tissues. …”

Deciphering multifaceted molecular mechanisms of matairesinol in inhibiting triple-negative breast cancer through comprehensive systems biology investigations by Amol Chaudhary (20475739)

“…<p>Triple-negative breast cancer (TNBC), characterized by the absence of Estrogen Receptor (ER), Progesterone Receptor (PR), and amplified HER2, represents an aggressive subtype devoid of targeted therapies, contributing to heightened mortality rates. …”

Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented... by Laia Bertran (3685147)